Publishing and publicity

If you are a journal publisher or editor, it's pretty much impossible to avoid controversy. There's the good kind: a well-argued disagreement on an important subject, or astounding new evidence that overturns an established theory, for example. But then there's the bad kind: an author who doesn't stick to your rules, a paper that doesn't hold up, or worse.The real test of a journal's mettle is not whether it manages to avoid the second type of controversy but rather, how well it copes with the f

Written byStephen Pincock
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

If you are a journal publisher or editor, it's pretty much impossible to avoid controversy. There's the good kind: a well-argued disagreement on an important subject, or astounding new evidence that overturns an established theory, for example. But then there's the bad kind: an author who doesn't stick to your rules, a paper that doesn't hold up, or worse.

The real test of a journal's mettle is not whether it manages to avoid the second type of controversy but rather, how well it copes with the fallout. A couple of recent examples of such coping mechanisms have made interesting viewing.

First, the Biological Society of Washington (BSW) stepped in a big heap of controversy when it published a paper on intelligent design (S.C. Meyer, "The origin of biological information and the higher taxonomic categories," Proc Biol Soc Wash, 117:213–39, Sept. 15, 2004). The article thrust the BSW's sleepy Proceedings (ISI ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies